• Tatiana Prokaeva, Elena S Klimtchuk, Polina Feschenko, Brian Spencer, Haili Cui, Eric J Burks, Roshanak Aslebagh, Khaja Muneeruddin, Scott A Shaffer, Elizabeth Varghese, John L Berk, and Lawreen H Connors.
• Amyloidosis Center, Boston University School of Medicine, Boston, MA, USA.
• Amyloid. 2023 Jun 1; 30 (2): 141152141-152.

BackgroundThe amyloidogenic transthyretin (TTR) variant, V122I, occurs in 4% of the African American population and frequently presents as a restricted cardiomyopathy. While heterozygosity for TTR V122I predominates, several compound heterozygous cases have been previously described. Herein, we detail features of ATTRv amyloidosis associated with novel compound heterozygous TTR mutation, T60I/V122I and provide evidence supporting the amyloidogenecity of T60I.MethodsA 63-year-old African American female presented with atrial fibrillation, congestive heart failure, autonomic and peripheral neuropathy. In vitro studies of TTR T60I and V122I were undertaken to compare the biophysical properties of the proteins.ResultsCongophilic deposits in a rectal biopsy were immunohistochemically positive for TTR. Serum screening by isoelectric focussing revealed two TTR variants in the absence of wild-type protein. DNA sequencing identified compound heterozygous TTR gene mutations, c.239C > T and c.424G > A. Adipose amyloid deposits were composed of both T60I and V122I. While kinetic stabilities of T60I and V122I variants were similar, distinct thermodynamic stabilities and amyloid growth kinetics were observed.ConclusionsThis report provides clinical and experimental results supporting the amyloidogenic nature of a novel TTR T60I variant. In vitro data indicate that the destabilising effect of individual T60I and V122I variants appears to be additive rather than synergistic.

22 keywords...

hide…